Medications in Pregnancy — Teratogenicity, Safe Antibiotics, and Anticoagulation

Teratogenicity refers to the ability of medications or substances to cause structural or functional abnormalities in developing fetuses. Drug safety during pregnancy is classified using the Pregnancy and Lactation Labeling Rule (PLLR), which replaced the former FDA pregnancy categories (A, B, C, D, X) in 2015.

[KEY_CONCEPT] The critical period for major organ malformations occurs during organogenesis (weeks 3-8 of gestation), while functional defects and growth abnormalities can occur throughout pregnancy.

PLLR Framework Components:

• Pregnancy: Risk summary, clinical considerations, and data
• Lactation: Risk summary, clinical considerations, and data
• Females and Males of Reproductive Potential: Contraception and infertility information

Teratogenic Risk Periods:

[HIGH_YIELD] Major Known Teratogens:

• ACE inhibitors/ARBs: Renal dysgenesis, oligohydramnios, growth restriction
• Warfarin: Warfarin embryopathy (nasal hypoplasia, bone stippling)
• Valproic acid: Neural tube defects (1-2% risk), facial dysmorphism
• Lithium: Ebstein anomaly (cardiac malformation)
• Isotretinoin: Multiple severe malformations
• Methotrexate: Neural tube defects, limb defects

[CLINICAL_PEARL] Always consider the timing of exposure, dose, and duration when assessing teratogenic risk. The absence of evidence is not evidence of safety.

Antimicrobial therapy during pregnancy requires balancing maternal infection treatment with fetal safety. Most bacterial infections can be effectively treated with pregnancy-safe antibiotics.

Safe Antibiotics (Generally Recommended):

β-lactams:

• Penicillins (amoxicillin, ampicillin, penicillin G/V)
• Cephalosporins (cephalexin, ceftriaxone, cefazolin)
• Limited data: Carbapenems (meropenem, imipenem)

Macrolides:

• Azithromycin, erythromycin: First-line for atypical organisms
• Clarithromycin: Limited data, use with caution

Other Safe Options:

• Clindamycin: Anaerobic coverage, C. difficile risk
• Nitrofurantoin: UTI treatment (avoid at term due to hemolysis risk)
• Fosfomycin: Single-dose UTI treatment

[HIGH_YIELD] Antibiotics to AVOID:

Special Considerations:

• Group B Strep prophylaxis: Penicillin G IV or ampicillin IV (first-line)
• Clindamycin for penicillin-allergic patients (if susceptible)
• Vancomycin for severe penicillin allergy with resistant organisms

[CLINICAL_PEARL] Nitrofurantoin should be avoided after 36 weeks due to risk of neonatal hemolysis in G6PD-deficient infants.

UTI Treatment Algorithm:

Pregnant patient with UTI symptoms ↓ Obtain urine culture ↓ Empiric treatment while awaiting culture:

• First-line: Nitrofurantoin 100mg BID × 5-7 days
• Alternative: Cephalexin 500mg QID × 7 days
• If allergic: Fosfomycin 3g single dose ↓ Adjust based on culture results ↓ Repeat urine culture 1-2 weeks after completion

Pregnancy creates a hypercoagulable state due to increased clotting factors, decreased protein S, and venous stasis. Anticoagulation management requires careful consideration of maternal and fetal safety.

[KEY_CONCEPT] Warfarin crosses the placenta and is teratogenic, while heparin products do not cross the placental barrier.

Safe Anticoagulants in Pregnancy:

Low Molecular Weight Heparin (LMWH) - FIRST-LINE

• Enoxaparin: Most commonly used
  • Treatment dose: 1 mg/kg Q12h or 1.5 mg/kg daily
  • Prophylactic dose: 40 mg daily
• Advantages: Predictable pharmacokinetics, lower HIT risk, subcutaneous administration
• Monitoring: Anti-Xa levels if indicated (renal impairment, extremes of weight)

Unfractionated Heparin (UFH)

• Indications: Patients with severe renal impairment, high bleeding risk
• Dosing: Weight-based protocols with aPTT monitoring
• Advantages: Rapid reversibility, can be used peripartum

Warfarin Considerations:

• Contraindicated in pregnancy (teratogenic weeks 6-12)
• Warfarin embryopathy: Nasal hypoplasia, stippled bone epiphyses
• CNS abnormalities possible throughout pregnancy

[HIGH_YIELD] Anticoagulation Indications in Pregnancy:

*Warfarin may be considered for mechanical valves after counseling about risks

Peripartum Management:

• Planned delivery: Discontinue LMWH 12-24 hours before
• Neuraxial anesthesia: Ensure 12+ hours since last LMWH dose
• Emergency delivery: Consider protamine reversal for UFH
• Postpartum: Resume anticoagulation 12-24 hours after delivery

[CLINICAL_PEARL] Direct oral anticoagulants (DOACs) like rivaroxaban and apixaban are NOT recommended in pregnancy due to limited safety data.

High-Risk Mechanical Valve Protocol:

Mechanical heart valve in pregnancy ↓ Multidisciplinary counseling (Cardiology, MFM, Anesthesia) ↓ Option 1: Therapeutic LMWH throughout pregnancy

• Monitor anti-Xa levels monthly
• Target anti-Xa 0.8-1.2 units/mL ↓ Option 2: Warfarin (after detailed counseling)
• Switch to LMWH weeks 6-12
• Resume warfarin after 12 weeks
• INR target per valve type ↓ Peripartum: Transition to UFH for delivery

Clinical decision-making for medication use in pregnancy involves systematic risk-benefit analysis, considering maternal condition severity, gestational age, and available alternatives.

Risk Assessment Framework:

[HIGH_YIELD] Key Questions for Medication Decisions:

1. What is the maternal risk of untreated condition?
2. What is the gestational age and critical exposure period?
3. Are there safer alternatives available?
4. What is the quality of safety data for this medication?
5. Can treatment be delayed until after delivery?

Common Clinical Scenarios:

Hypertension Management:

• Safe options: Methyldopa (first-line), labetalol, nifedipine
• Avoid: ACE inhibitors, ARBs (renal dysgenesis risk)
• Limited data: Hydralazine (acute use acceptable)

Depression/Anxiety Treatment:

• Preferred SSRIs: Sertraline, fluoxetine
• Avoid: Paroxetine (cardiac defects), benzodiazepines (cleft palate risk)
• Considerations: Maternal mental health vs. neonatal adaptation syndrome

Asthma Management:

• Safe: Albuterol, budesonide, prednisone
• Continue pre-pregnancy controllers - untreated asthma more dangerous than medications

Diabetes Management:

[CLINICAL_PEARL] Insulin requirements increase significantly during pregnancy due to placental hormones causing insulin resistance.

Medication Counseling Points:

• Baseline risk: 3-5% major birth defects in general population
• Most medications: Have limited pregnancy data
• Timing matters: Greatest risk during organogenesis
• Benefit-risk ratio: Maternal health affects fetal health

Documentation Requirements:

• Informed consent for medications with known risks
• Risk-benefit discussion notes
• Alternative options considered
• Consultation with appropriate specialists when indicated

[KEY_CONCEPT] The goal is optimizing maternal health while minimizing fetal risk - not avoiding all medications during pregnancy.

Emergency Medication Considerations:

• Life-threatening conditions: Maternal stabilization takes priority
• Cardiac arrest: Standard ACLS medications acceptable
• Severe infections: Broad-spectrum antibiotics as needed
• Anaphylaxis: Epinephrine is safe and life-saving

Preconception Counseling:

• Folic acid supplementation: 400-800 mcg daily (higher doses for high-risk patients)
• Medication review: Optimize regimens before conception
• Teratogen avoidance: Discontinue harmful medications
• Immunizations: Update vaccines before pregnancy

Certain maternal conditions and pregnancy complications require specialized medication management approaches with enhanced monitoring and multidisciplinary care.

Chronic Medical Conditions:

Epilepsy Management:

• Safer anticonvulsants: Lamotrigine, levetiracetam
• Higher risk: Valproic acid (neural tube defects), phenytoin (fetal hydantoin syndrome)
• Folic acid: 4-5 mg daily (higher dose due to folate antagonism)
• [HIGH_YIELD] Monitor drug levels closely - pregnancy alters pharmacokinetics

Autoimmune Conditions:

• Hydroxychloroquine: Safe for lupus, can prevent flares
• Sulfasalazine: Safe for IBD maintenance
• Corticosteroids: Prednisone preferred (less placental transfer than betamethasone)
• Avoid: Methotrexate, mycophenolate, biologics (case-by-case basis)

Psychiatric Medications:

Pregnancy-Specific Conditions:

Preeclampsia Management:

• Magnesium sulfate: Seizure prophylaxis, neuroprotection
  • Loading: 4-6g IV over 20 minutes
  • Maintenance: 2g/hour IV continuous
  • Monitor reflexes, respiratory rate, urine output
• Antihypertensives: Labetalol, hydralazine, nifedipine immediate-release

Preterm Labor:

• Tocolytics: Nifedipine (first-line), terbutaline
• Corticosteroids: Betamethasone for fetal lung maturation
• Magnesium sulfate: Neuroprotection <32 weeks

[CLINICAL_PEARL] Medication absorption and metabolism change significantly during pregnancy due to:

• Increased plasma volume (dilution effect)
• Enhanced renal clearance
• Altered hepatic metabolism
• Delayed gastric emptying

Peripartum Complications:

Postpartum Depression:

• Breastfeeding considerations: Sertraline, paroxetine have lower milk transfer
• Avoid: Fluoxetine (long half-life, accumulation in infant)
• Monitor infant: For sedation, feeding difficulties

Postpartum Hemorrhage:

• Oxytocin: First-line uterotonic
• Methylergonovine: Avoid in hypertension
• Misoprostol: Alternative uterotonic
• Tranexamic acid: Antifibrinolytic, reduces bleeding

Lactation Drug Safety:

• LactMed database: Reliable resource for breastfeeding safety
• Timing strategies: Dose after feeding, pump and dump if needed
• Monitor infant: Weight gain, alertness, feeding patterns

[KEY_CONCEPT] Most medications are compatible with breastfeeding - benefits of breastfeeding usually outweigh minimal drug exposure risks.

Emergency Situations:

• Maternal cardiac arrest: Standard ACLS, early delivery if ≥20 weeks
• Severe allergic reactions: Epinephrine is safe and life-saving
• Status epilepticus: Standard anticonvulsants (lorazepam, phenytoin)
• Diabetic ketoacidosis: Intensive insulin therapy, avoid oral agents